You are here

  • Home
  • Online First
  • Response to: ‘Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis’ by Lee and Song

Article Text

Article menu

other Versions

Download PDFPDF
Correspondence response
Response to: ‘Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis’ by Lee and Song
  1. Yoshikazu Nakaoka
  1. Correspondence to Dr Yoshikazu Nakaoka, Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka 565-8565, Japan; ynakaoka{at}ncvc.go.jp

https://doi.org/10.1136/annrheumdis-2017-212871

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I thank Lee and Song1 for their thoughtful comments on our recent publication.2 The authors state that our study did not examine the steroid-sparing effect of tocilizumab because of mandatory glucocorticoid tapering. Given that the dose reduction rate of glucocorticoid significantly correlates with the relapse rate,3 this randomised, double-blind, placebo-controlled study was designed with mandatory glucocorticoid tapering to investigate whether tocilizumab treatment enables glucocorticoid tapering without relapse of Takayasu arteritis. Although the primary endpoint, …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributor YN wrote the response to the eLetter.

    • Funding This study was funded by Chugai Pharmaceutical Co. Funding for manuscript preparation was provided by F. Hoffmann-La Roche.

    • Competing interests YN reports personal fees from Chugai as a consultant of the sponsor-initiated clinical trial (Chugai Pharmaceutical Co.) using tocilizumab for Takayasu arteritis; grants and personal fees from Chugai; grants and personal fees from Astellas, Pfizer, and MSD outside the submitted work; grants from Takeda, Otsuka, Bayer outside the submitted work; and personal fees from Daiichi Sankyo and Kowa Pharmaceutical Co. outside the submitted work.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles